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Background: CTBT (7-chlorotetrazolo [5,1-c]benzo[1,2,4]triazine) increases efficacy of commonly used antifungal
agents by an unknown mechanism. It increases the susceptibility of Saccharomyces cerevisiae, Candida albicans and
Candida glabrata cells to cycloheximide, 5-fluorocytosine and azole antimycotic drugs. Here we elucidate CTBT
mode of action with a combination of systematic genetic and transcriptome analysis.
Results: To identify the cellular processes affected by CTBT, we screened the systematic haploid deletion mutant
collection for CTBT sensitive mutants. We identified 169 hypersensitive deletion mutants. The deleted genes
encode proteins mainly involved in mitochondrial functions, DNA repair, transcription and chromatin remodeling,
and oxidative stress response. We found that the susceptibility of yeast cells to CTBT depends on molecular
oxygen. Transcriptome analysis of the immediate early response to CTBT revealed rapid induction of oxidant and
stress response defense genes. Many of these genes depend on the transcription factors Yap1 and Cin5. Yap1
accumulates rapidly in the nucleus in CTBT treated cells suggesting acute oxidative stress. Moreover, molecular
calculations supported a superoxide generating activity of CTBT. Superoxide production in vivo by CTBT was found
associated to mitochondria as indicated by oxidation of MitoSOX Red.
Conclusion: We conclude that CTBT causes intracellular superoxide production and oxidative stress in fungal cells
and is thus enhancing antimycotic drug effects by a secondary stress.
Background
Fugal pathogens pose a serious threat to immunocom-
promised persons. Despite many antifungal agents inter-
fering with metabolism and growth of fungal cells a
limited number of compounds are being used for treat-
ment of mycotic diseases caused by human pathogenic
fungal species. Over the past two decades, the number
of invasive fungal infections has increased in the clinical
setting. Candida sp. is the fourth most common patho-
gen identified, and other pathogens such as Cryptococ-
cus sp., Aspergillus sp., and Fusarium sp., have a high
morbidity and mortality. In addition, the incidence of
mycoses caused by opportunistic fungi is rising [1].
CTBT, 7-chlorotetrazolo [5,1-c]benzo[1,2,4]triazine, has
antifungal activity and enhances the efficacy of other
antifungals with different targets such as cycloheximide,
fluconazole or 5-fluorocytosine [2]. The molecular
mechanism of CTBT action has not yet been resolved.
Currently used antifungals belong to three major
classes of agents: azoles, polyenes, and echinocandines
[3]. These compounds target ergosterol biosynthesis,
membrane functions and cell wall biosynthesis. Addi-
tionally, other currently applied compounds are the pyr-
imidine, 5-fluorocytosine (5-FC), which acts by
inhibiting RNA and DNA synthesis [4] and ciclopiroxo-
lamine which seems to induce oxidative stress and iron
deprivation [5]. The intrinsic resistance of human fungal
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dins are effective in Candida prevention and offer a
greater spectrum of activity across the various Candida
species, including also C. krusei and C. glabrata,w h i c h
are not reliably covered by azoles e.g. fluconazole [6].
Fungal drug resistance mechanisms involve decreased
drug uptake, increased drug export, overexpression or
structural modification of the drug target protein [7,8].
Reversal of antifungal drug effectiveness in yeast cells
mediated by efflux has been reported for a variety of
substances targeting different molecular processes.
These are for example the immunosuppressive agents
FK506 and cyclosporine [9-13]. To overcome drug resis-
tance of human fungal pathogens, new antifungals with
novel cellular targets [14] and multidrug resistance
reversal agents rendering drug resistant strains sensitive
to commercially used antifungals are being developed
[15,16] but have not surfaced as yet. Studies evaluating
combinations of antifungals have shown synergistic and
additive activity. However, caution is required, because
some antifungal combinations have demonstrated antag-
onistic activity. Controlled clinical trials are still neces-
sary to explore the various efficacious antifungal
combinations [17]. Since the common antifungals are
mainly targeting membrane and cell wall components,
efficient combination therapy might be reached by
involving substances with an alternative mode of action.
The site and mode of CTBT action have not yet been
resolved. CTBT displayed a weak antifungal activity
which was unaffected by deletion of the PDR1 and
PDR3 genes encoding the main transcription activators
involved in the control of multidrug resistance in Sac-
charomyces cerevisiae [18,19]. Yeast cells grown in its
presence had altered sterol composition and were more
sensitive to this compound in the yap1Δ genetic back-
ground [2]. Here we report insights gained for the mode
of CTBT action by systematic identification of yeast
genes required for resistance to CTBT in combination
with transcriptome analysis. We will show that CTBT
causes an unexpected dramatic response to oxidative
stress including damage to mitochondria and genomic
DNA. These results provide a model for CTBT action
and indicate that its synergic effect with commonly used
antifungal drugs is due to the combination of oxidative
and other stresses.
Results
CTBT action depends on molecular oxygen and is
connected by mitochondrial functions
CTBT has been shown to display cytotoxic activity and
the ability to enhance the activity of several antifungal
agents at sub-inhibitory concentrations [2]. In disk diffu-
sion assay on YPD medium using the S. cerevisiae
BY4741 wild type and its rho
- mutant strains CTBT
induced the formation of clear growth inhibition zones
that were surrounded by outer inhibition zones corre-
sponding to reduced yeast growth (Figure 1A, B).
Growth inhibition zones of respiring cells growing on
YPGE medium containing glycerol plus ethanol were
significantly larger compared to those with fermenting
cells on YPD. This suggested that CTBT disrupted mito-
chondrial functions (Figure 1C). Essentially the same
results were obtained with the BY4742 and FY1678-28C
wild type strains (data not shown). On the other hand,
S. cerevisiae yeast cells grown anaerobically were found
to be insensitive to CTBT. As expected for qualitative
anaerobicity of our experimental setup, both strains
failed to grow anaerobically without ergosterol and
unsaturated fatty acids. No inhibition zones were
observed when cells of the BY4741 and BY4742 wild
Figure 1 CTBT induced growth inhibition zones on complex
media. S. cerevisiae BY4741 wild type on YPD. (A), BY4741 rho
-
mutant on YPD (B), BY4741 on YPGE (C), BY4741 (D) and BY4742 (E)
grown anaerobically on YPD supplemented with ergosterol plus
Tween 80. Amounts of CTBT per disk were: 5 μg (left part in A and
B), 10 μg (right part in A, B and C-E).
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Page 2 of 16type strains were grown in the absence of molecular
oxygen on YPD medium supplemented with ergosterol
and unsaturated fatty acids (Figure 1D, E). These results
clearly indicate that mitochondrial functions and mole-
cular oxygen are involved in the CTBT susceptibility in
yeast cells.
Identification of yeast deletion mutants with increased
CTBT susceptibility
To gain more insight into CTBT action we systemati-
cally identified mutants with altered sensitivity. We
screened the S. cerevisiae haploid deletion mutant col-
lection for altered growth in the presence of CTBT. The
wild type strain BY4741 from which the EUROSCARF
collection has been derived was unable to grow on YPD
medium supplemented with 6 μg/ml of CTBT. There-
fore, the hypersensitive mutant strains were identified
on YPD media containing 2 and 4 μg/ml of CTBT.
Using pin replicator, cells of each mutant strain grown
in YPD medium containing G418 sulphate were repli-
cated as quadruplets to CTBT containing medium and
to YPD control plate. After 6 days of growth the mutant
strains sensitive to 2 or 4 μg/ml of CTBT were identi-
fied, collected and their sensitivity to CTBT confirmed
in independent assays. This screen of the 4700 haploid
gene deletion mutants was carried out once and resulted
in the isolation of 169 CTBT hypersensitive mutant
strains (Additional file 1).
Significantly, some molecular complexes or biochem-
ical pathways were represented by more than one
mutant (Table 1). In order to assign cellular functions
contributing to CTBT tolerance we searched for
enriched gene ontology (GO) categories according to
the SGD GO-Termfinder. The most prominent GO
terms associated to the genes required for CTBT toler-
ance were functions related to mitochondria, transcrip-
tion, DNA repair, and stress response (Table 2).
The largest group of strains hypersensitive to CTBT
contained deletions in genes for mitochondrial biogen-
esis and functions, including DNA replication (MIP1),
mRNA processing (MRS1), protein synthesis and proces-
sing (AFG3, DIA4, MRPL49, MRPS35, MSY1, MTG1,
OCT1, PCP1, RML2, RSM19, TUF1), respiration (CYT1),
ATP synthesis (A T P 1 ,A T P 1 1 ,A T P 1 2 ,A T P 1 8 ), Fe/S
protein biosynthesis (ISA1, ISA2), superoxide dismuta-
tion (SOD1, SOD2) and others.
In the second largest group were mutants in genes
involved in gene expression thus hinting at an acute
transcriptional response to CTBT. Identified genes are
involved in chromatin remodeling (ARP5, HOS2, HTZ1,
RSC1, SGF73, SNF2, SWI3, SWI4, YAF9), transcription
(C T K 1 ,M E D 2 ,R O X 3 ,R R N 1 0 ,R T F 1 ,S P T 4 ,S P T 2 0 ,
SRB5, TAF14, THO2) or encode transcription factors
involved in oxidative stress response (YAP1, YAP7,
SKN7) and lipid biosynthesis (OPI1).
We identified at least 11 CTBT sensitive strains con-
taining deletion in DNA repair genes, including those
involved in homologous recombination and repair
(MMS1, MMS4, RAD50, RAD51, RAD52, RAD57),p o s t
replication repair (RAD6, RAD18), double strand break
repair (MRE11, XRS2), excision repair (MET18)a n d
others. Importantly, deletion of genes encoding func-
tions in lipid metabolism also impaired CTBT tolerance.
These are involved in ergosterol (DAP1, ERG2, ERG3,
Table 1 Functions of selected genes deleted in CTBT sensitive mutant strains
Function Gene (ORF) name
Mitochondrial functions ADH1, AFG3, ATP1, ATP11, ATP12, ATP18, CIT1, CYT1, DIA4, IMP1, ISA1, ISA2, MAS37, MDM32, MDM38, MGM1, MIP1,
MRPL49, MRPS35, MRS1, MSY1, MTG1, OCT1, PCP1, PDC1, PHB1, RML2, RSM19, SOD1, SOD2, TUF1, YDR115W, YGL085W
Chromatin remodeling and
transcription
ARP5, CDC73, CTK1, HOS2, HPR1, IES6, MED2, MGA2, OPI1, PGD1, RRN10, RME1, ROX3, RSC1, RTF1, RTT109, SGF73, SKN7,
SNF2, SPT4, SPT20, SRB5, STP1, SWI3, SWI4, TAF14, THO2, UME6, YAF9, YAP1, YAP7
DNA repair MET18, MMS1, MMS4, MRE11, RAD6, RAD18, RAD50, RAD51, RAD54, RAD57, XRS2
Lipid metabolism AKR1, CHO1, CHO2, DAP1, ERG2, ERG3, ERG6, ERG24, MGA2, OPI1
Stress response and signal
transduction
ASC1, BCK1, CCS1, CTR1, CYS3, NBP2, REG1, SKN7, SNF1, SOD1, SOD2, YAP1, YAP7
Vacuolar functions AVT4, CWH36, KCS1, TFP1, TFP3, VMA4, VMA21, VMA22
Protein sorting and
degradation
DIA2, MAP1, PRE9, RAD6, VPS15, VPS20, VPS34
Amino acid metabolism CYS3, ILV1, PRO2, TRP2, TRP3, TRP5
Transport AVT4, CTR1, MUP1, TAT1
Mannosyl transferases ANP1, OCH1
Pentose phosphate pathway GND1, RPE1
Ungrouped ARD1, BEM1, BIM1, BUB3, BUD25, BUD27, BUR2, CDC50, CIK1, CSM1, CTF18, ENV6, FYV10, GEP4, GET2, HTZ1, KRE28,
MTC5, NAT1, NAT3, NCE101, NPT1, NRP1, NUP133, ORM2, PHO85, RAI1, RCY1, REF2, RGI1, RNR4, RPL1B, RPL2A, RPL42B,
RTC1, SBH1, YIM2
Unknown functions YDR049W, YDR114C, YHR045W, YNR065C, YOR305W
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Page 3 of 16ERG6, ERG24), fatty acid (MGA2) and phospholipid bio-
synthesis (CHO1, CHO2, OPI1). Along with superoxide
dismutase encoding genes, SOD1 and SOD2, which have
a primary role in superoxide radical detoxification, other
genes involved in oxidative stress response were also
identified. The CCS1 gene encodes the specific copper
chaperone delivering the copper to Sod1. The CTR1
gene is coding for a high affinity copper transporter of
the plasma membrane. The transcription factors YAP1,
YAP7 and SKN7 are involved in transcriptional regula-
tion of oxidative stress response genes including SOD1,
SOD2 and others. Additional functions required for
CTBT tolerance involve vacuolar metabolism, protein
sorting, amino acid metabolisms and others (Table 1).
Importantly, many genes with CTBT defense functions
overlap with those involved in menadion, hydrogen per-
oxide and arsenic stress tolerance [20-23].
The results of phenotypic profiling and the oxygen
dependence of CTBT action, led us to the suggestion
that CTBT induces reactive oxygen species in yeast cells.
Transcriptional profile analysis of CTBT treated yeast cells
Profiles of transcriptional responses can be used to iden-
tify cellular defense processes. We therefore investigated
the immediate response of wild type BY4741 cells trea-
t e dw i t hC T B T .W eu s e dad o s e1 / 3
rd of the minimal
inhibitory concentration (6 μg/ml) 2 μg/ml in a time
curse of 5, 10, 20 and 40 min in liquid medium. Expres-
sion data were collected from duplicate arrays. We iden-
tified 314 genes induced in at least one time point by
more than 2 fold and 186 genes repressed more than 2
fold (Additional file 2 and 3). Repressed genes com-
prised many genes with functions in protein biosynthesis
(Table 3). This has been observed previously in tran-
script profiles from cells treated with various other com-
pounds or exposed to stressful conditions [24] and
correlates frequently with repression of Sfp1 function
[25,26]. Most ribosomal protein genes were repressed to
about half of the level of exponentially growing cells.
The induction kinetics had an early and a delayed tran-
scriptional wave. Notably, the genes with eminent anti-
oxidant functions were induced most rapidly. Many
induced genes were linked to mitochondrial functions
and oxidative stress response (Figure 2A, S1). We
further predicted the possible transcription factors
involved. T-profiler based analysis revealed that among
the induced genes some transcription factor binding
s i t e sw e r eh i g h l ye n r i c h e d[ 2 7 , 2 8 ] .T h e s ew e r et h eg e n -
eral stress transcription factors Msn2 and Msn4, but
more prominently the oxidative stress response factors
Yap1, Skn7, Yap7, and Cin5/Yap4 (Table 4). Especially
many Yap1 and Skn7 targeted genes were evident in the
immediate early response genes. Moreover, a number of
Cin5/Yap4 target genes were found to establish a second
non-overlapping oxidative stress regulon (Figure 2B).
Among the CTBT repressed genes we noticed a number
of genes involved in the ergosterol biosynthesis (Figure
2 C )a n dt h et a r g e to fa z o l e sa n t i f u n g a l s ,t h ee n z y m e
lanosterol 14-alpha-demethylase Erg11p. To demon-
strate a general effect on these genes we show the
expression profiles of the genes associated to the GO-
term lipid biosynthesis (Figure 2C).
Next we analyzed the connection between transcript
and phenotype profiles (Figure 3A). Generally, phenoty-
pic display data do not have large overlaps with tran-
script profile data. This is due to the fact that pathways
activate many target genes in parallel with sometime
redundant functions. However, in some cases the over-
lap is informative since it points to exceptionally impor-
tant nodes of stress resistance [29]. Here we found a
small number of genes both required for tolerance and
significantly induced. They encode proteins required
for several different mitochondrial functions: ISA2,a
protein required for maturation of mitochondrial and
cytosolic Fe/S proteins, ATP1, the alpha subunit of the
H
+ATPase, SOD1 the cytosolic superoxide dismutase,
CCS1 the copper chaperone for Sod1p and SOD2,t h e
mitochondrial superoxide dismutase. This overlap points
to an essential response to CTBT originating from or
localized to mitochondria. Furthermore, the transcrip-
tion factors Srb5, Yap1 and Yap7 are induced also at the
level of transcription (Figure 3A). Comparison of 169
genes required for resistance to CTBT, and 689 required
for hydrogen peroxide, menadione, mefloquine, and
Table 2 GO-terms significantly enriched in the 169 genes
required for CTBT tolerance (SGD GO-termFinder).
GO_term Frequency P-value
response to stimulus 27.2% 2.28E-06
transcription 23.1% 2.73E-06
response to stress 20.1% 6.35E-05
DNA repair 10.7% 0.00096
organelle organization (mitochondrion) 29.6% 0.0033
Table 3 GO-terms significantly enriched in the 500 > 2





RNA polymerase complex 2.0% 0.0093
response to oxidative stress 5.40% 2.39E-09
monosaccharide catabolic process 3.40% 1.14E-05
response to chemical stimulus 11.40% 1.31E-05
cell redox homeostasis 1.60% 6.20E-05
alcohol metabolic process 6.60% 0.0012
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Page 4 of 16Figure 2 Transcript profiles of CTBT treated yeast cells. Exponentially growing cells were treated with 2 μgm l
-1 CTBT for the indicated times
and microarrays of treated versus untreated cells were done in triplicates. Expression data of genes associated to the GO-term stress response
(A), genes regulated and targeted by Yap1 and Cin5 according to Harbison et al., 2004 [27] (B), and the GO-term lipid biosynthetic process (C)
were clustered. Enriched GO-terms associated to the respective genes are indicated as colored bars. The full expression dataset is available as
supplementary file.
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Page 5 of 16ibuprophen reistance [22] showed a significant overlap
(86 genes, cumulative hypergeometric probability
P<1 0
-30; Figure 3B, C). We could not detect a signifi-
cant bias of genes required for resistance to hydrogen
peroxide, menadione, mefloquine, and ibuprophen in
our dataset, indicating induction of general oxidative
stress by CTBT.
Yap1 accumulates rapidly in the nucleus in cells
exposed to oxidative stress [30]. We followed the intra-
cellular distribution of Yap1-GFP construct and found a
similar rapid accumulation of Yap1 in both CTBT and
hydrogen peroxide stressed cells (Figure 4A, B). Taken
together the transcript profiling data support the pheno-
typic display by pointing to an immediate oxidative
stress response and furthermore to an important protec-
tive function of superoxide scavenging and mitochon-
drial activity.
Mitochondrial superoxide production and petite mutant
formation in CTBT treated yeast cells
S. cerevisiae mutant strains deleted in the SOD1 or
SOD2 genes were found to be the most sensitive to
CTBT. The minimal inhibitory concentrations of CTBT
determined by broth dilution method for the sod1Δ and
sod2Δ mutants (0.5 μg/ml) were 10-times reduced com-
pared to the wild type strain. Thus, we suspected that
CTBT induces superoxide formation. To determine this
directly, MitoSOX Red was used to assess superoxide
radical production in live cells. This dye is selectively
targeted to the mitochondria where it is selectively oxi-
dized by superoxide and exhibits red fluorescence upon
binding to nucleic acids [31]. As shown in Figure 5A, a
large fraction of wild type cells grown for 12 h in YPGal
medium in the presence of sub-inhibitory concentra-
tions of CTBT accumulated the dye and fluoresced
intensively red, compared with control cells grown in
the absence of CTBT. Analysis of individual cells under
a fluorescence microscope revealed cells with mitochon-
drial fluorescence. In addition, a small fraction of cells
showed red brilliant fluorescence, which may represent
severely damaged or dead cells [32] (Figure 5B). A high
percentage of cells exhibiting mitochondrial fluorescence
was also observed in the population of the sod2Δ
mutant strain treated with a 10-times lower concentra-
tion of CTBT. In the genetic background of the S. cere-
visiae EG103 strain the sod1Δ mutant cells were
significantly more sensitive to CTBT compared with the
sod2Δ cells. These results demonstrate that CTBT
induces an increased production of superoxide that may
disturb many cellular functions by damaging nucleic
acids, oxidizing proteins and causing lipid peroxidation.
In fact, when the sod2Δ mutant cells were grown for 24
h in YPD medium containing a sub-inhibitory concen-
tration of CTBT the respiration deficient petite mutants
were induced in high frequency indicating the damage
to mtDNA induced by CTBT (Table 5). Both the CTBT
treatment and the absence of Sod1 or Sod2 result in
increased ROS formation [33,34]. It was also possible
that CTBT mediated inactivation of Sod1p and/or
Sod2p might contribute partly to the observed ROS for-
mation. To assess the role of superoxide dismutases, the
isogenic series of the sod1Δ, sod2Δ and sod1Δ sod2Δ
mutant strains derived from the S. cerevisiae EG103
wild type strain were used in zone inhibition assay with
CTBT (5 μg per disk) on YPD. We observed that sensi-
tivity of the sod1Δ sod2Δ double mutant cells was
slightly higher compared to the sod1Δ mutant (Figure
5C). We conclude that enhanced ROS production by
CTBT treatment is counteracted by both superoxide
dismutases.
Theoretical treatment of CTBT activity
In order to get more insight into the mechanism of
CTBT induced superoxide generation we used the stan-
dard computational protocol to perform quantum chemi-
cal calculations of 6 tetrazolo- and triazolobenzotriazines
described previously [2]. To compare the important
structural parameters and their influence on the biologi-
cal activity, the unsubstituted [1,2,4] triazolo [3,4, c]
benzo[1,2,4]triazine (compound 3)w a sa d d e dt ot h eo r i -
ginal series. Four parameters that could be related to bio-
logical activity of compounds were chosen. LogP models
the transport of molecules in biological systems, μ is the
dipole moment of isolated molecule in Debye units,
HOMO (Highest Occupied Orbital) and LUMO (Lowest
Unoccupied Orbital) stand for energy of frontier orbitals
in eV units.
As shown in Figure 6, CTBT is predicted to yield the
lowest values of dipole moment, HOMO orbital energy
and mainly very low value of LUMO orbital energy
compared with another compounds under study. The
value of LUMO energy appears to be the most impor-
tant calculated parameter for possible explanation of
CTBT activity related to its antifungal effect expressed
as the diameter of the growth inhibition zone (DGIZ). If
o n ee l e c t r o nr e d u c t i o nw o u l db ea s s u m e da st h ef i r s t
step in CTBT mediated superoxide production, the low
Table 4 Transcription factor binding sites enriched in
CTBT regulated genes.
Motif Name t-value E-value Mean ORFs
TTASTAA YAP1 4.91 1.30E-04 0.713 82
AGGGG MSN2-4 4.72 3.40E-04 0.611 120
MTTAYRTAAK CIN5 4.46 1.20E-03 1.235 17
CCCCT MSN2-4 4 9.20E-03 0.57 118
CGATGAG PAC -6.48 1.30E-08 -0.344 58
AAAATTT rRPE -6.57 7.30E-09 -0.039 156
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Page 6 of 16Figure 3 Comparison of phenotypic and expression profiles. A) Enriched GO-terms in the 169 genes deleted in the CTBT sensitive mutant
strains are indicated in the left panels. Sensitivity levels to 2 and 4 μg/ml CTBT are colour coded as indicated. GO, sensitivity and expression
data were hierarchical clustered. Genes belonging to two clusters which are highly expressed and the corresponding mutants highly sensitivity
are enlarged and indicate involvement of superoxide dismutases and oxidative stress specific transcription factors. B) Comparison of CTBT
sensitive strains to hydrogen peroxide, menadion, mefloquine and ibuprophen sensitive strains. Fitness values (log2 transformed) from [22] were
clustered with CTBT sensitivity values (2 very sensitive, 1 sensitive, 0 insensitive). To visualize all genes included in these graphs in TreeView, the
raw data are available as supplementary files. C) A Venn diagram shows the overlap between CTBT and datasets from Tucker and Fields [22].
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Page 7 of 16Figure 4 Analysis of Yap1-GFP localization in CTBT-treated cells. Exponentially growing yeast cells (EG103) were exposed for indicated time
to CTBT (4 μg/ml) and hydrogen peroxide (4 mM) as a positive control. Nuclear localization of Yap1-GFP was verified by co-localization with
nuclei stained with DAPI (2 μg/ml) (A). For each sample, at least 100 cells were scored for subcellular localization of Yap1-GFP. Open bars
represent cells with cytoplasmic Yap1-GFP, hatched bars represent cells with nuclear Yap1-GFP (B). Data are presented as the average of the two
independent experiments.
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Page 8 of 16Figure 5 Superoxide production and growth inhibition in CTBT treated cells. Fluorescence of oxidized MitoSOX Red was determined using
fluorescence spectrometry (A) and fluorescence microscopy (B). The values represent the means of 3 independent experiments. Open bars
represent cells grown without CTBT. Wild-type cells (BY4741) were grown in the presence of 2 μg/ml (hatched bars) and 4 μg/ml (filled bars)
CTBT. sod1Δ mutant cells were grown in the presence of 0.25 μg/ml (hatched bars) and 0.4 μg/ml (filled bars) CTBT. sod2Δ mutant cells were
grown in the presence of 0.25 μg/ml CTBT (hatched bars). (C) Growth inhibition zones of CTBT in mutant strains lacking the indicated
superoxide dismutase genes was scored after 5 days incubation.
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Page 9 of 16value of LUMO energy makes the electron transfer into
LUMO of CTBT leading to CTBT radical easily
possible.
In the chemical structure of studied molecules there
are two structural characteristics that decrease signifi-
c a n t l yt h eL U M O - e n e r g yi . e .c h l o r i n ea t o ma n dt e t r a -
zolo ring that both are incorporated into CTBT.
Consequently, CTBT appears as the main candidate for
redox cycling and superoxide generation among the
studied molecules. These calculations and the genetic
data show that CTBT has a capacity to generate super-
oxide radicals with reducing equivalents possible derived
from the respiratory chain.
Discussion
In this study we show that CTBT, a compound enhan-
cing the antifungal activity of several drugs [2], gener-
ates superoxide and other reactive oxygen species (ROS)
and induces massive oxidative stress in yeast cells which
enhances the antifungal activity of several unrelated
drugs.
Five lines of evidence suggest that CTBT produces
oxidative stress via generation of superoxide. First,
CTBT toxicity required molecular oxygen. Second, it
has predicted molecular properties of a molecule cap-
able of redox cycling. Third, we detected oxidative stress
using the two in vivo reporters MitoSOX Red and Yap1-
GFP. Fourth, genetic evidence was provided by the isola-
tion of characteristic mutants with defects in oxidative
stress scavenging functions. Fifth, transcription profiling
showed activation of regulons associated with oxidative
stress response. CTBT activity was strictly dependent on
the presence of molecular oxygen because no inhibition
Table 5 Respiration deficient mutant formation in yeast
cultures grown for 24 h in YPD medium containing
indicated concentrations of CTBT








The results are means of two experiments.
Figure 6 Structure, calculated theoretical data and growth inhibition caused by CTBT and related compounds.L o gP :p a r t i t i o n
coefficient in octanol-water system; μ: dipole moment of isolated molecule; HOMO: energy of the Highest Occupied Molecular Orbital; LUMO:
energy of the Lowest Unoccupied Molecular Orbital. DGIZ: diameter of growth inhibition in zone inhibition assay on solid medium caused by
CTBT [5 μg added to paper disk (diameter of 6 mm)]. CTBT: 7-chlorotetrazolo [5,1-c]benzo[1,2,4]triazine; 1: tetrazolo [5,1-c]benzo[1,2,4]triazine;
2: 7-methyltetrazolo [5,1-c]benzo[1,2,4]triazine; 3: [1,2,4]triazolo [3,4, c]benzo[1,2,4]triazine; 4: 7-chloro[1,2,4]triazolo [3,4, c]benzo[1,2,4]triazine;
5: 1-bromo[1,2,4]triazolo [3,4, c]benzo[1,2,4]triazine.
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Page 10 of 16of growth by this drug was observed under strictly anae-
robic conditions.
Antifungal activity of CTBT was higher on media con-
taining glycerol plus ethanol instead of glucose indicat-
ing that developed functional mitochondria might be
involved in drug action. This implies that apart from
superoxide anion radical (O2
.-) and ROS generation
CTBT does not have other direct cytotoxic effects. ROS
affect many cellular functions by damaging nucleic
acids, oxidizing proteins and causing lipid peroxidation
[35,36]. Dismutation of superoxide into hydrogen perox-
ide and molecular oxygen is catalyzed by two superoxide
dismutases: the Cu, Zn-depending Sod1p localized in
the cytosol and the mitochondrial intermembrane space
and the Mn-depending Sod2p which is localized in the
mitochondrial matrix [37]. Among the gene deletion
strains selected for increased CTBT sensitivity (Addi-
tional file 1), the sod1Δ and sod2Δ mutant strains were
found to be the most sensitive. Additionally, the
mutants deleted for SOD1 and CCS1, a copper chaper-
one essential for Sod1p maturation, had a similar phe-
notype. CTBT could act as an inhibitor of Sods. Since
the sod1Δsod2Δ double mutant cells were also sensitive
to CTBT the Sod1p and Sod2p superoxide dismutases
c a n n o tb et h ep r i m a r yt a r g e t so fC T B Ta c t i o n .T h e r e -
fore, CTBT is a producer of superoxide in presence of
oxygen.
CTBT could either directly be a reducing agent or,
alternatively, as a cofactor in the context of an enzyme.
Our genetic data suggest that CTBT is not acting via a
single enzyme because such deletion mutants would be
resistant to CTBT and could be easily isolated by
genetic means. In fact, in similar screen we were unable
to find deletion mutants resistant to CTBT used at the
concentration of 10 μg/ml. However, the possibility of a
redundant enzymatic activity exists plus the requirement
of reducing equivalents. In intact cells, the superoxide
anion radical (O2
.-) is the precursor of most ROS and is
generated under specific bioenergetic conditions at sev-
eral sites within the mitochondrial electron-transport
system. Most of superoxide is converted to H2O2 and
oxygen inside and outside the mitochondrial matrix by
superoxide dismutases [36,38]. Non-mitochondrial
sources of ROS involve cytochrome b5 reductase,
NADPH oxidases, lipoxygenases, monoamine oxidases,
xanthine oxidase and others [36,37]. In S. cerevisiae,t h e
main sites of mitochondrial superoxide formation are
one NADH:ubiquinone oxidoreductase located in the
inner mitochondrial membrane and facing the matrix
[39], two NADH:ubiquinone oxidoreductases facing the
mitochondrial intermembrane space and the ubiquinol:
cytochrome c reductase [40]. This is in line with our
scheme proposing CTBT induced superoxide generation
in mitochondria (Figure 7). Furthermore, paraquat, the
herbicide generating superoxide by redox cycling, is
principally reduced by mitochondrial NADH dehydro-
genases [41].
Most identified genes required for increased CTBT
susceptibility were found to be involved in mitochon-
drial biogenesis and function, DNA repair, gene expres-
sion, lipid metabolism and stress response (Table 1).
Many of them are known to be involved in defense pro-
cesses protecting yeast cells against oxidative stress
[35,37] and have been previously identified in genome-
wide analyzes of yeast deletion mutant strains sensitive
to oxidative stress induced by a superoxide generator
menadione, hydrogen peroxide, organic peroxides
[20-22], arsenite and cadmium [23].
Remarkable is a high frequency of CTBT hypersensi-
tive deletion mutants with affected mitochondrial func-
tions. A requirement of energy for the repair of
oxidatively damaged molecules has previously been pro-
posed to explain why petite mutants are more sensitive
to oxidative stress than wild type strains [42]. On the
other hand one cannot rule out a higher permeability of
mitochondrial membranes for CTBT, superoxide or
other ROS generated in dysfunctional mitochondria.
The increased damage to mutant mitochondria caused
by ROS may also reduce the mitochondrial membrane
potential under critical level resulting in the arrest of
mitochondrial biogenesis required for growth of eukar-
yotic cells [43].
Other significant pathways involved in CTBT suscept-
ibility were also identified by the presence of several
genes involved in the same pathway or encoding the
subunits of the particular cellular complexes. This con-
cerns genes involved in the RAD52 and RAD6 epistasis
groups of DNA repair, Paf1 complex of RNA polymer-
ase II (CDC73, HPR1 and RTF1), protein sorting to
vacuole (VPS15, VPS34), vacuolar ATPase (TFP1, TFP3,
VMA4, VMA21, VMA22), N-terminal acetyltransferases
(ARD1, NAT1, NAT3) acetylating many proteins
involved in cell cycle, heat shock resistance, mating,
sporulation and telomere silencing as well as genes
involved in ergosterol metabolism (DAP1, ERG2, ERG3,
ERG6 and ERG24) and tryptophan biosynthesis (TRP2,
TRP3 and TRP5). Along with tryptophan, interruption
of the synthesis of cystein, isoleucin and proline also
enhanced the CTBT toxicity. The sensitivity displayed
by corresponding mutant strains is apparently not the
result of the absence of the amino acids because CTBT
was toxic on YPD plates that contain all necessary
amino acids. It is possible that the accumulation of
intermediates enhances the effect of CTBT.
The overlay of expression data with phenotypic data
pointed mainly to superoxide dismutase activity (Sod1,
Sod2, Ccs1) and second to the activation of transcrip-
tion factors Yap1, Cin5/Yap4, and Yap7. Yap1p is a
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drug resistance and oxidative stress response [44]. Reac-
tive oxygen species (ROS) generated both from
endogenous and exogenous sources induce accumula-
tion of Yap1p in the nucleus resulting in enhanced tran-
scription of many genes involved in removing or
detoxifying ROS. Cin5/Yap4 is activated by oxidative
stress [45] like Yap1. The contribution of Yap7 to tran-
scription is less understood. Yap7 is involved in tran-
scriptional activation of the SOD1, SOD2 and CCS1
genes (http://yeastract.com;[27]). However, we found no
transcriptional induction of DNA damage specific genes
and possibly because this stress type does not surface
within the observed time frame. These findings suggest
a highly focused primary effect of CTBT on oxidative
stress and delayed effects on other pathways.
CTBT enhances activity of several drugs [2]. This
synergy becomes perhaps clearer when considering the
production of superoxide and other ROS. Our phenoty-
pic screen showed an enhanced sensitivity of mutants in
the RAD52 and RAD6 e p i s t a s i sg r o u p so fD N Ar e p a i r .
5-Fluorocytosine is a drug which enters nucleotide
metabolism and damages the cells by interfering with
dNTP and mRNA synthesis. CTBT could act at two
levels. Oxidative damage might cause DNA damage and
at the same time hamper deoxynucleotide synthesis
requiring glutathione or thioredoxin for production via
ribonucleotide reductase. Azoles and terbinafin both tar-
get ergosterol synthesis. Interestingly, CTBT reduces
transcription of most genes for the enzymes of the path-
way. Finally, CTBT might exacerbate cycloheximide
inhibition on translation by reduction of synthesis of
ribosomal protein genes. Oxidative stress causes inacti-
vation of the target of rapamycin complex 1 (TORC1)
and thus inactivation of the Sfp1, one major activator of
transcription of ribosomal protein genes. An interaction
with the popular echinocandines remains to be shown.
Up to now the combination of antifungals has been
tried in vitro in many different combinations. The appli-
cation of combinations may reduce costs, and
Figure 7 Scheme of proposed CTBT induced superoxide generation in mitochondria. Nde, external NADH dehydrogenase; Ndi, internal
NADH dehydrogenase; Sdh, succinate dehydrogenase complex; Q, ubiquinone; bc1, cytochrome bc1 complex; c, cytochrome c; aa3, cytochrome
c oxidase. In this model CTBT is reduced to CTBT
.- radical by accepting an electron from the NADH dehydrogenases or the cytochrome bc1
complex.
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dal activity (for review see [17]). Apart from combina-
tions of classical antifungals (amphotericin B, azoles,
echinocandines), unusual combinations lead to unex-
pected results as for example in the case of azoles plus
calcineurin inhibitors [46] or with membrane active
compounds [47].
Conclusions
CTBT, apart from its weak antifungal activity, is able to
strongly inhibit the proliferation of multidrug resistant
yeast cells in combination with subinhibitory concentra-
tions of other antifungals. Its mode of action depending
on the molecular oxygen has been resolved using the
combination of two genome-wide approaches including
the screening of yeast deletion library for CTBT hyper-
sensitivity mutants and transcriptome analysis of yeast
cells exposed to this drug. We found that CTBT induces
an increased production of superoxide and oxidative
stress associated with damage to mitochondria and
genomic DNA. Yeast cells deleted in nonessential genes
encoding proteins involved mainly in mitochondrial
function, DNA repair, transcription and oxidative stress
response are hypersensitive to CTBT. CTBT rapidly
induces transcription of oxidant and stress response
defense genes activated mainly by Yap1 and Yap4/Cin5
transcription factors.
The exact molecular mechanism of CTBT action,
associated with superoxide generation in mitochondria,
is not known so far. It does not require a complete and
functional respiratory chain as demonstrated by CTBT
sensitivity of rho
- mutant cells. Theoretical treatment of
CTBT activity revealed that this compound might be
amenable to one electron reduction. Electrons donated
from mitochondrial NADH dehydrogenases or cyto-
chrome bc1 complex can lead to CTBT anion radical
formation that can be re-oxidized by molecular oxygen
generating superoxide probable on the both sides of the
inner mitochondrial membrane (Figure 7). Our com-
bined genome wide approaches show the power of yeast
genetics and transcript profiling to define mode of func-
tioning of bioactive substances.
Methods
Strains and culture conditions
The following yeast strains were used:S. cerevisiae
strains FY1679-28C (MATa ura3-52 trp1-63 leu2-1
his3-20) [48], BY4741 (MATa his3Δ1l e u 2 Δ0m e t 1 5 Δ0
ura3Δ0), BY4742 (MATa his3Δ1l e u 2 Δ0m e t 1 5 Δ0
ura3Δ0), the complete set of deletion mutants derived
from the haploid strain BY4741 (EUROSCARF, http://
web.uni-frankfurt.de/fb15/mikro/euroscarf), EG103
(MATa leu2-3,112 his3Δ1t r p 1 - 2 8 9u r a 3 - 5 2 ), EG118
(EC103 with sod1ΔA::URA3), EG110 (EC103 with sod2::
TRP1), EG133 (EC103 with sod1ΔA::URA3 sod2::TRP1)
[49]. A plasmid expressing an N-terminal GFP-Yap1
fusion was obtained from M. Toledano [50]. Cells were
grown in YPD medium containing 2% (w/v) glucose, 1%
(w/v) yeast extract, 2% (w/v) peptone, in YPGal medium
(as YPD but 2% (w/v) galactose instead of 2% glucose),
in YNB medium containing 2% (w/v) glucose 0.67%
yeast nitrogen base without amino acids (Difco), in
YPGE medium (as YPD but 2% glycerol plus 2% ethanol
instead of 2% glucose). The media were solidified with
2% (w/v) bacto agar. Where appropriate, amino acids,
uracil, ergosterol (20 μg/ml), Tween 80 (0.06%, w/v) or
G418 sulphate (200 μg/ml) was added. For induction of
rho
-/rho
0 mutants, cells were grown in YPD containing
of ethidium bromide (25 μg/ml) or CTBT for 24 h,
diluted and plated onto solid YPD. Frequency of respira-
tion deficient mutants in yeast culture was determined
after staining colonies with TTC (triphenyltetrazolium
chloride) or replica plating onto YPGE plates.
Drug susceptibility testing
Susceptibility of yeast cells to CTBT was determined
using the spot test assay. Aliquots of yeast cultures were
spotted onto YPD plates containing the indicated con-
centrations of CTBT. Plates were incubated at 30°C for
6 days. In liquid media, susceptibilities to CTBT were
assayed by the broth microdilution method in 96 well
plate containing 200 μl YPD supplemented with differ-
ent concentrations of CTBT. The growth at 30°C was
scored after 24 and 48 h. Susceptibility to CTBT was
also assessed using zone inhibition assays. Approxi-
mately 10
7 cells were plated onto YPD media, the filter
discs (diameter of 6 mm) soaked with indicated amounts
of CTBT were placed on the plates which were incu-
bated at 30°C for 3-6 days before determination of the
diameter of the zone of growth inhibition.
Screening for altered CTBT susceptibility
The collection of viable gene deletion mutants in the
BY4741 background was screened for both CTBT
hypersensitive and CTBT resistant strains. EUROSCARF
mutant strains were transferred from 96 well master
plates to solid YPD media supplemented with G418 sul-
phate. After 3 days, cells from grown colonies were
inoculated into the corresponding wells of a 96 well
microtiter plates containing 200 μl YPD supplemented
with G418 sulphate. Cells were cultured 24 h at 30°C,
diluted 20-times in YPD medium containing G418 sul-
phate and replica pinned onto YPD control plates and
plates containing different concentration of CTBT (2
and 4 μg/ml) using a 96 floating pin replicator. The
mutant strains were arranged in quadruplet to create a
dilution in a given square giving a total of 96 strains pla-
ted per agar plate. The plates were incubated at 30°C
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strains to CTBT was assessed visually from the growth
on the test medium relative to the growth on YPD con-
trol plate. To pin-point cellular functions that confer
altered CTBT susceptibility, we searched for functional
categories in the sensitive gene set according to FunCat
at MIPS http://mips.gsf.de. Gene ontology (GO) analysis
was done using GO Term Finder in SGD http://yeast-
genome.org.
Microarray analysis
Wild type BY4741 cells were grown for 4 generations
in YPD at 30°C to OD600 of 1 before CTBT solution (2
mg/ml) was added to a final concentration of 2 μg/ml.
After 5, 10, 20 and 40 minutes cells were harvested,
washed in ice-cold water and immediately frozen. RNA
was isolated by the hot phenol method. 20 μgo ft o t a l
RNA was used for direct labeling cDNA synthesis with
either Cy3-dCTP or Cy5-dCTP. Labeled cDNAs were
purified with GFX columns (GE Healthcare). Hybridi-
zation to cDNA microarrays (Ontario Cancer Institute,
Toronto, Canada) was done in triplicates with color
inversion in 60 μl DigEasyHyb solution (Roche, Man-
nheim, Germany) overnight at 37°C. After hybridiza-
tion, microarrays were washed three times in 1 × SSC,
and 0.1% SDS at 50°C for 10 min, followed by 1 min
in 1 × SSC und 0.1 × SSC at room temperature and 5
min 500 rpm spin to dryness. Microarrays were ana-
lyzed on an Axon 4000B scanner (Invitrogen, Molecu-
lar Devices) with Gene Pix Pro 4.1 (Axon; Molecular
Probes).
For individual microarrays the intensity of the two
fluorescent channels were normalized to the mean of
ratio of medians of all unflagged features using the Gen-
epix Pro 4.1 normalization option. Values of not found
features were excluded from further analysis. Genes
labeled as dubious ORFs in SGD were also removed
from analysis. Mean ratios were calculated for features
with at least 4 values. The filtered normalized values
used for further analysis are available as supplementary
file. Cluster analysis [51,52]http://bonsai.ims.u-tokyo.ac.
jp/~mdehoon/software/cluster/software.htm was per-
formed using the cluster3 and visualized with TreeView
[53]http://jtreeview.sourceforge.net. Significant associa-
tions to either GO-terms or transcription factors were
obtained by GO-Term Finder at SGD http://www.yeast-
genome.org and T-Profiler http://www.t-profiler.org
[28]. TreeView files corresponding to the figures are
s u p p l i e da sA d d i t i o n a lf i l e s3 ,4 ,5 ,6 ,7 ,8 .V a l u e so f
genes associated with the most significant terms were
visualized by Cluster analysis using complete linkage
and correlation as similarity metric. GO assignments
were graphically included in the cluster analysis by
setting their column weight value to zero. Microarray
data have been deposited at ArrayExpress http://www.
ebi.ac.uk/microarray with the accession E-MEXP-2307.
Fluorescence microscopy and spectrometry
Intracellular ROS production was examined using Mito-
SOX Red (Molecular Probes). MitoSOX Red is a lipid
soluble cation that accumulates in the mitochondrial
matrix where it can be oxidized to a fluorescent product
by superoxide [31]. Yeast strains from initial concentra-
tion of 2 × 10
6c e l l s / m lw e r eg r o w ni nY P G a lm e d i u m
containing indicated concentration of CTBT. After 12 h
of growth aliquots of 10
9 cells were washed twice with
phosphate-buffered saline (PBS) and incubated in the
dark for 20 min in 5 μM MitoSOX Red. Cells were
washed three times with PBS, resuspended in PBS and
the percentage of cells positively stained with MitoSOX
Red was determined by fluorescence microscopy using a
Zeiss Axioplan 2 fluorescence microscope (Thornwood,
NY). Images were recorded on fluorescence microscope
with a Spot Pursuit camera (Visitron Systems, Puch-
heim, Germany). Fluorescence of cells was also deter-
mined using fluorescence spectrometer (Jasco FP-6300,
Tokyo) with excitation and emission wavelengths of 510
and 580 nm, respectively. Nuclei were stained by addi-
tion of 1 μl/ml Hoechst 33342 (Molecular Probes). GFP
was visualized in live cells approximately 5 minutes after
treatment with CTBT without fixation using excitation
and emission wavelengths of 355 and 465 nm,
respectively.
Quantum chemical calculations
The usual computational protocol for quantum chemical
calculations was used. The optimal geometries of the
molecules were obtained by complete geometry optimi-
zation employing the AM1 method. This geometry was
used as input for the single SCF calculations by the ab
Initio method (minimal STO-3G basis set) to obtain the
energies and wave functions [54].
Additional file 1: CTBT sensitive mutant strains. A pdf file containing
all identified CTBT hypersensitive gene deletion mutants.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-
153-S1.PDF]
Additional file 2: Clustered CTBT induced genes. Contains the
graphics of the clustered transcript profile results from 500 significantly
induced or repressed genes.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-
153-S2.PDF]
Additional file 3: Cluster data for figure S1. Contains the text
information to reconstruct figure S1 with TreeView.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-
153-S3.CDT]
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Page 14 of 16Additional file 4: Cluster data for figure 2A containing genes
associated to the GO-term stress response. Contains the text
information to reconstruct figure 2A with TreeView.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-
153-S4.CDT]
Additional file 5: Cluster data for figure 2B containing genes
regulated and targeted by Yap1 and Cin5. Contains the text
information to reconstruct figure 2B with TreeView.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-
153-S5.CDT]
Additional file 6: Cluster data for figure 2C containing genes
associated to the GO-term lipid biosynthetic process. Contains the
text information to reconstruct figure 2C with TreeView.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-
153-S6.CDT]
Additional file 7: Cluster data for figure 3A showing enriched GO-
terms in 169 genes required for CTBT resistance. Contains the text
information to reconstruct figure 3A with TreeView.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-
153-S7.CDT]
Additional file 8: Cluster data for figure 3B comparing CTBT
sensitive strains to hydrogen peroxide, menadion, mefloquine and
ibuprophen sensitive strains. Contains the text information to
reconstruct figure 3B with TreeView.




cDNA: complementary DNA; CTBT: 7-chlorotetrazolo [5,1-c]benzo[1,2,4]
triazine; DAPI: 4’,6-diamidino-2-phenylindole; GFP: green fluorescent protein;
GO: gene ontology; HOMO: highest occupied orbital; LUMO: lowest
unoccupied orbital; mtDNA: mitochondrial DNA; NADH(P): nicotinamide
adenine dinucleotide (phosphate); ORF: open reading frame; PBS: phosphate
buffered saline; ROS: reactive oxygen species; SDS: sodium dodecyl sulfate;
SGD: Saccharomyces genome database; SSC: saline-sodium citrate buffer.
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